Last update 21 Mar 2026

SHR-1139

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
Anti-IL-23p19/IL-36R bispecific antibody(Jiangsu Hengrui Pharmaceutical ), SHR-1139
Target
IL-23p19 x IL-36R
Action
inhibitors
Mechanism
IL-23p19 inhibitors(Interleukin-23 subunit p19 inhibitors), IL-36R inhibitors(Interleukin-36 receptor inhibitors)
Therapeutic Areas
Immune System DiseasesDigestive System DisordersSkin and Musculoskeletal Diseases+ [1]
Active Indication
Pyoderma GangrenosumUlcerative colitis, active moderateUlcerative colitis, active severe+ [3]
Inactive Indication-
Originator Organization
Guangdong Hengrui Pharmaceutical Co., Ltd.
Active Organization
Guangdong Hengrui Pharmaceutical Co., Ltd.Jiangsu Hengrui Pharmaceutical Group Co. Ltd.Jiangsu Hengrui Pharmaceutical Group Co. Ltd.Atridia Pty Ltd.
+ [1]
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

6
Clinical Trials associated with SHR-1139
NCT07444684
/ Not yet recruitingPhase 2
A Phase II Clinical Study to Evaluate the Efficacy, Safety and Pharmacokinetics of SHR-1139 Injection in Adult Patients With Pyoderma Gangrenosum
NCT07337564
/ Not yet recruitingPhase 2IIT
A Clinical Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative Pyoderma Gangrenosum
NCT07232576
/ RecruitingPhase 2
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of SHR-1139 in Patients With moderate-to- Severe Active Ulcerative Colitis.
100 Clinical Results associated with SHR-1139
Login to view more data
100 Translational Medicine associated with SHR-1139
Login to view more data
100 Patents (Medical) associated with SHR-1139
Login to view more data
100 Deals associated with SHR-1139
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pyoderma GangrenosumPhase 2
China
Guangdong Hengrui Pharmaceutical Co., Ltd.
05 Mar 2026
Ulcerative colitis, active moderatePhase 2
China
Guangdong Hengrui Pharmaceutical Co., Ltd.
01 Dec 2025
Ulcerative colitis, active severePhase 2
China
Guangdong Hengrui Pharmaceutical Co., Ltd.
01 Dec 2025
Plaque psoriasisPhase 2
China
Guangdong Hengrui Pharmaceutical Co., Ltd.
28 Mar 2025
PsoriasisPhase 1
Australia
Atridia Pty Ltd.
19 Aug 2025
Autoimmune DiseasesPreclinical
China
Jiangsu Hengrui Pharmaceuticals Co., Ltd.Jiangsu Hengrui Pharmaceuticals Co., Ltd.
24 Oct 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free